Director, Rutgers Center for Pharmacoepidemiology and Treatment Science
Professor of Medicine (Infectious Diseases) and Epidemiology, Robert Wood Johnson Medical School
Vincent Lo Re is a pharmacoepidemiologist and Director of the Rutgers Center for Pharmacoepidemiology and Treatment Science (PETS). Dr. Lo Re earned his BS from Georgetown University and his MD from the University of Pennsylvania. He completed his internship and residency in Internal Medicine at the University of Pennsylvania, where he also served as Chief Medical Resident. Following his residency training, Dr. Lo Re completed a fellowship in Infectious Diseases at the Hospital of the University of Pennsylvania. During his fellowship training, he received a Master of Science in Clinical Epidemiology, focusing on pharmacoepidemiology, from the University of Pennsylvania. Upon completion of his clinical and research fellowship, Dr. Lo Re joined the faculty of the University of Pennsylvania in 2008, where he remained until joining Rutgers as Director of PETS in August 2025.
Dr. Lo Re conducts pharmacoepidemiology research, particularly related to infectious diseases and chronic liver diseases. He pioneered the use of electronic healthcare data for the study of acute and chronic liver diseases, particularly viral hepatitis. Dr. Lo Re was the first to develop computable phenotypes for many liver-related diseases, such as decompensated cirrhosis, hepatocellular carcinoma, cholangiocarcinoma, hepatic steatosis, severe acute liver injury, and acute liver failure events using electronic health data. The application of these methods led to the conduct of important pharmacoepidemiologic studies by Dr. Lo Re, including examining the impact of HIV viral suppression with antiretroviral therapy on end-stage liver disease outcomes, measuring and evaluating adherence to antiviral therapies, and identifying important adverse effects of antiviral therapies. His team was the first to create the cascade of care of hepatitis C infection, and the first to report on the disparities in access to the new direct-acting antiviral therapies for chronic hepatitis C infection. His research contributed to the removal of restrictions on reimbursements to these therapies, particularly for Medicare beneficiaries.
During the COVID-19 pandemic, Dr. Lo Re collaborated with the U.S. Food and Drug Administration Sentinel System, applying his expertise in infectious diseases pharmacoepidemiology to examine COVID-19-related complications. He co-led the development of a Master Protocol to create cohorts of patients with COVID-19 within the integrated health systems and national claims insurers of the FDA Sentinel System and to identify COVID-19-related comorbidities and complications. Under his leadership, his team applied this protocol to conduct seminal studies examining the epidemiology of COVID-19-related coagulopathy.
Most recently, Dr. Lo Re’s team has evaluated the impact of drug-induced liver injury. This research led to high impact publications, including the first population-based study evaluating the incidence of drug-induced acute liver failure, the first study to demonstrate the hepatic safety of statins regardless of HIV and/or chronic hepatitis status, the development of prognostic models to estimate the risk of acute liver failure in patients with drug-induced liver injury, and a new method to measure incidence rates of hospitalization for severe acute liver injury following initiation of potentially hepatotoxic medications.
Dr. Lo Re has more than 15 years of scholarly research utilizing healthcare data. His research has received a number of awards and honors, including selection as the 2016 recipient of the HIV Medicine Association Research Award; the Harold I. Feldman Distinguished Faculty Award from the Penn Department of Biostatistics, Epidemiology, and Informatics in 2021; and the COVID-19 Pharmacoepidemiology Research Award from the International Society for Pharmacoepidemiology in 2022.
In addition to his research accomplishments, Dr. Lo Re is a valued mentor and teacher and an advocate for early-stage investigators. He has been Co-Director of Penn’s Master of Science in Clinical Epidemiology Degree Program since 2018, and he has provided research training and mentorship to pharmacoepidemiology trainees as co-PI of Penn’s NIH-funded Pharmacoepidemiology T32 training program. His exceptional efforts in teaching have been recognized by his graduate students, who twice awarded him the Excellence in Teaching Epidemiology Award in 2010 and 2014. In further recognition of his consistently outstanding teaching, he was awarded the 2013 Leonard Berwick Memorial Teaching Award, one of Penn Medicine’s Awards of Excellence, and the Harvey M. Friedman Infectious Diseases Faculty Mentoring Award in 2021.
Dr. Lo Re is a Fellow of the International Society for Pharmacoepidemiology (ISPE) and served as its President from 2021-2022. He has also served as Regional Editor for the America’s of the Society’s journal, Pharmacoepidemiology & Drug Safety, since 2018. He has been Chair of the US FDA Drug Safety and Risk Management Advisory Committee since 2022. He also served as Co-Chair of the Infectious Diseases Society of America/American Association for the Study of Liver Diseases Hepatitis C Guidance Panel from 2022-2025.